SCHEMBL2763151

SCHEMBL2763151

COc1ccc2nnc(Cl)n2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.58
ALDH1A1 P00352 2/20 0.58
HSD17B10 Q99714 2/20 0.57
HPGD P15428 1/20 0.57
MALT1 Q9UDY8 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
DYRK1A Q13627 6/20 0.39
DYRK3 O43781 5/20 0.39
DYRK2 Q92630 5/20 0.39
DYRK1B Q9Y463 4/20 0.39
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
CCNT1 O60563 3/20 0.38
CDK9 P50750 3/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2764161 0.81 KDM4E (0.54) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL11572650 0.81 KDM4E (0.54) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL10490635 0.79 KDM4E (0.63) KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD
SCHEMBL18596494 0.79 L3MBTL1 (0.67) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL10764328 0.78 KDM4E (0.57) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL14832891 0.76 L3MBTL1 (0.60) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3723330 0.76 SMN1; SMN2 (0.57) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL612506 0.74 KDM4E (1.00) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3724867 0.74 MALT1 (0.54) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL14832187 0.73 LRRK2 (0.51) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-54110325-A None JP disclosed
US-9321777-B2 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors SANOFI (FR) 2016-04-26 US disclosed
US-20150344484-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS SANOFI-AVENTIS (FR) 2015-12-03 US disclosed
US-9115134-B2 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors SANOFI (FR) 2015-08-25 US disclosed
US-20140005189-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS SANOFI (FR) 2014-01-02 US disclosed
US-8546393-B2 6-triazolopyridazine sulfanyl benzothiazole derivatives as MET inhibitors SANOFI (FR) 2013-10-01 US disclosed
US-20100298315-A1 NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS SANOFI-AVENTIS (FR) 2010-11-25 US disclosed
EP-2178881-A2 NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS Sanofi-Aventis (FR) 2010-04-28 EP disclosed
WO-2009056692-A2 NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed
JP-S54110325-A NON-MEDICAL MICROBICIDE NIPPON NOHYAKU CO LTD 1979-08-29 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344484-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS MET, TPMT, MERTK KDM4E 711/4885MEN1 1118/4885KMT2A 996/4885
US-20140005189-A1 NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS MET, TPMT, MERTK KDM4E 711/4885MEN1 1118/4885KMT2A 996/4885
US-20100298315-A1 NOVEL 6-TRIAZOLOPYRIDAZINESULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND APPLICATION AS MEDICAMENTS AND PHARMNACEUTICAL COMPOSITIONS AND NOVEL USE AS MET INHIBITORS BMX, MET, TPMT KDM4E 752/4885MEN1 2500/4885KMT2A 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.